Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-25-078447
Filing Date
2025-05-28
Accepted
2025-05-28 17:28:42
Documents
5

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 26664
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 51293
3 EX-99.4 ck0000000000-ex99_4.pdf EX-99.4 342561
4 EX-99.6 ck0000000000-ex99_6.pdf EX-99.6 291707
5 EX-99.7 ck0000000000-ex99_7.pdf EX-99.7 20148
  Complete submission text file 0000950170-25-078447.txt   1001316
Mailing Address 4225 EXECUTIVE SQUARE SUITE 600 LA JOLLA CA 92037
Business Address 4225 EXECUTIVE SQUARE SUITE 600 LA JOLLA CA 92037 858-247-0520
Zura Bio Ltd (Subject) CIK: 0001855644 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-92696 | Film No.: 25996684
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ACCESS INDUSTRIES, INC. 40 WEST 57TH STREET, 28TH FLOOR NEW YORK NY 10019
Business Address C/O ACCESS INDUSTRIES, INC. 40 WEST 57TH STREET, 28TH FLOOR NEW YORK NY 10019 212-247-6400
AI Biotechnology LLC (Filed by) CIK: 0001942670 (see all company filings)

EIN.: 842172770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D